@article{ref1,
title="A practical utility and benefit of pharmacogenetic-based antidepressant treatment strategy for major depressive disorder patients with difficult-to-treat",
journal="Clinical psychopharmacology and neuroscience",
year="2021",
author="Lee, K.H. and Bahk, W.-m. and Lee, S.-j. and Serretti, A. and Pae, C.-u.",
volume="19",
number="1",
pages="160-165",
abstract="OBJECTIVE: We report the results of pharmacogenomics-based antidepressant treatment (PGXt) results in treating treatment- resistant major depressive disorder (TRD) patients in real practice. <br><br>METHODS: Nine patients were prescribed Neuropharmagen? for selection of antidepressants for individual patient and their clinical outcomes were followed. <br><br>RESULTS: After treatment by PGXt results from current antidepressants, substantial reduction of depressive symptoms was observed at some point and maintained during observation period in six patients. <br><br>CONCLUSION: Our case series potentially shows the clinical utility and benefit of PGXt for treatment of TRD patients. © 2021 Korean College of Neuropsychopharmacology. All rights reserved.<p /><p>Language: en</p>",
language="en",
issn="1738-1088",
doi="10.9758/CPN.2021.19.1.160",
url="http://dx.doi.org/10.9758/CPN.2021.19.1.160"
}